FSD Non Current Liabilities Total vs Net Receivables Analysis

HUGE Stock

USD 0.32 0.01 3.03%

FSD Pharma financial indicator trend analysis is much more than just examining FSD Pharma Class latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether FSD Pharma Class is a good investment. Please check the relationship between FSD Pharma Non Current Liabilities Total and its Net Receivables accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in FSD Pharma Class. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

Non Current Liabilities Total vs Net Receivables

Non Current Liabilities Total vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of FSD Pharma Class Non Current Liabilities Total account and Net Receivables. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between FSD Pharma's Non Current Liabilities Total and Net Receivables is -0.21. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Net Receivables in the same time period over historical financial statements of FSD Pharma Class, assuming nothing else is changed. The correlation between historical values of FSD Pharma's Non Current Liabilities Total and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of FSD Pharma Class are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Non Current Liabilities Total i.e., FSD Pharma's Non Current Liabilities Total and Net Receivables go up and down completely randomly.

Correlation Coefficient

-0.21

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Non Current Liabilities Total

Net Receivables

Most indicators from FSD Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into FSD Pharma Class current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in FSD Pharma Class. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

The current year's Sales General And Administrative To Revenue is expected to grow to 183.55, whereas Discontinued Operations is forecasted to decline to (1.3 M).

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	4.1M	5.0M	2.6M	3.5M
Interest Income	1.3K	367.7K	932.6K	886.0K

Depreciation And Amortization Interest Income

FSD Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Long Term Investments	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total
Total Assets		0.2	0.52	0.98	0.65	-0.58	0.76	0.88	0.03	0.67	0.75	0.48	0.06	0.18	0.13	0.68	0.7	0.51	0.45	0.36	0.89	0.41	0.76	0.73	0.08	0.69
Other Current Liab	0.2		0.76	0.04	0.17	-0.49	0.31	-0.1	0.54	0.2	0.27	0.3	0.37	-0.25	0.44	-0.21	0.29	0.76	-0.05	0.04	-0.01	0.05	0.26	0.28	-0.08	0.05
Total Current Liabilities	0.52	0.76		0.34	0.01	-0.45	0.46	0.27	0.22	0.21	0.26	0.2	0.06	-0.34	0.53	0.26	0.3	1.0	-0.1	0.08	0.34	0.14	0.49	0.3	-0.13	0.07
Total Stockholder Equity	0.98	0.04	0.34		0.71	-0.54	0.72	0.9	-0.01	0.69	0.77	0.49	0.05	0.27	0.02	0.68	0.71	0.33	0.51	0.38	0.9	0.41	0.73	0.74	0.12	0.74
Net Tangible Assets	0.65	0.17	0.01	0.71		-0.72	0.61	0.6	0.42	0.69	0.88	0.78	0.57	0.35	-0.32	0.28	0.81	0.0	0.43	0.29	0.64	0.35	0.43	0.85	0.1	0.63
Retained Earnings	-0.58	-0.49	-0.45	-0.54	-0.72		-0.75	-0.47	-0.62	-0.4	-0.87	-0.91	-0.71	0.31	0.14	-0.36	-0.93	-0.44	0.13	0.04	-0.61	-0.08	-0.27	-0.94	0.38	-0.22
Accounts Payable	0.76	0.31	0.46	0.72	0.61	-0.75		0.57	0.22	0.55	0.82	0.56	0.32	-0.1	0.17	0.54	0.81	0.46	0.19	0.34	0.65	0.4	0.44	0.77	0.08	0.5
Cash	0.88	-0.1	0.27	0.9	0.6	-0.47	0.57		-0.2	0.44	0.6	0.48	-0.06	0.22	-0.21	0.81	0.58	0.26	0.25	0.12	0.97	0.19	0.55	0.66	-0.05	0.45
Net Receivables	0.03	0.54	0.22	-0.01	0.42	-0.62	0.22	-0.2		0.3	0.5	0.57	0.91	-0.21	-0.01	-0.2	0.49	0.21	-0.11	-0.09	0.0	-0.05	0.09	0.47	-0.29	0.05
Good Will	0.67	0.2	0.21	0.69	0.69	-0.4	0.55	0.44	0.3		0.68	0.42	0.26	0.59	0.09	0.18	0.59	0.19	0.56	0.36	0.46	0.36	0.86	0.57	0.35	0.71
Common Stock Total Equity	0.75	0.27	0.26	0.77	0.88	-0.87	0.82	0.6	0.5	0.68		0.83	0.59	0.0	-0.11	0.43	0.98	0.24	0.27	0.22	0.7	0.29	0.48	0.96	-0.13	0.6
Common Stock Shares Outstanding	0.48	0.3	0.2	0.49	0.78	-0.91	0.56	0.48	0.57	0.42	0.83		0.74	-0.15	-0.34	0.28	0.9	0.19	-0.14	-0.17	0.58	-0.05	0.23	0.93	-0.4	0.17
Short Term Investments	0.06	0.37	0.06	0.05	0.57	-0.71	0.32	-0.06	0.91	0.26	0.59	0.74		-0.21	-0.24	-0.06	0.61	0.06	-0.19	-0.1	0.14	-0.02	-0.04	0.61	-0.28	0.0
Non Current Liabilities Total	0.18	-0.25	-0.34	0.27	0.35	0.31	-0.1	0.22	-0.21	0.59	0.0	-0.15	-0.21		-0.19	-0.06	-0.14	-0.35	0.63	0.35	0.11	0.27	0.49	-0.09	0.66	0.45
Inventory	0.13	0.44	0.53	0.02	-0.32	0.14	0.17	-0.21	-0.01	0.09	-0.11	-0.34	-0.24	-0.19		-0.18	-0.13	0.54	0.23	0.25	-0.2	0.12	0.23	-0.21	0.31	0.25
Other Current Assets	0.68	-0.21	0.26	0.68	0.28	-0.36	0.54	0.81	-0.2	0.18	0.43	0.28	-0.06	-0.06	-0.18		0.43	0.25	-0.06	-0.09	0.87	-0.02	0.35	0.49	-0.26	0.13
Other Stockholder Equity	0.7	0.29	0.3	0.71	0.81	-0.93	0.81	0.58	0.49	0.59	0.98	0.9	0.61	-0.14	-0.13	0.43		0.29	0.08	0.08	0.69	0.17	0.41	0.99	-0.25	0.45
Total Liab	0.51	0.76	1.0	0.33	0.0	-0.44	0.46	0.26	0.21	0.19	0.24	0.19	0.06	-0.35	0.54	0.25	0.29		-0.11	0.09	0.33	0.14	0.47	0.29	-0.12	0.07
Long Term Investments	0.45	-0.05	-0.1	0.51	0.43	0.13	0.19	0.25	-0.11	0.56	0.27	-0.14	-0.19	0.63	0.23	-0.06	0.08	-0.11		0.78	0.17	0.68	0.47	0.08	0.67	0.92
Short Long Term Debt	0.36	0.04	0.08	0.38	0.29	0.04	0.34	0.12	-0.09	0.36	0.22	-0.17	-0.1	0.35	0.25	-0.09	0.08	0.09	0.78		0.06	0.98	0.26	0.05	0.76	0.75
Total Current Assets	0.89	-0.01	0.34	0.9	0.64	-0.61	0.65	0.97	0.0	0.46	0.7	0.58	0.14	0.11	-0.2	0.87	0.69	0.33	0.17	0.06		0.13	0.56	0.76	-0.17	0.41
Short Term Debt	0.41	0.05	0.14	0.41	0.35	-0.08	0.4	0.19	-0.05	0.36	0.29	-0.05	-0.02	0.27	0.12	-0.02	0.17	0.14	0.68	0.98	0.13		0.26	0.15	0.65	0.69
Intangible Assets	0.76	0.26	0.49	0.73	0.43	-0.27	0.44	0.55	0.09	0.86	0.48	0.23	-0.04	0.49	0.23	0.35	0.41	0.47	0.47	0.26	0.56	0.26		0.42	0.22	0.58
Common Stock	0.73	0.28	0.3	0.74	0.85	-0.94	0.77	0.66	0.47	0.57	0.96	0.93	0.61	-0.09	-0.21	0.49	0.99	0.29	0.08	0.05	0.76	0.15	0.42		-0.27	0.42
Property Plant Equipment	0.08	-0.08	-0.13	0.12	0.1	0.38	0.08	-0.05	-0.29	0.35	-0.13	-0.4	-0.28	0.66	0.31	-0.26	-0.25	-0.12	0.67	0.76	-0.17	0.65	0.22	-0.27		0.5
Short Long Term Debt Total	0.69	0.05	0.07	0.74	0.63	-0.22	0.5	0.45	0.05	0.71	0.6	0.17	0.0	0.45	0.25	0.13	0.45	0.07	0.92	0.75	0.41	0.69	0.58	0.42	0.5

Click cells to compare fundamentals

FSD Pharma Account Relationship Matchups

FSD Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	44.0M	42.0M	63.0M	38.4M	17.4M	23.9M
Total Current Liabilities	7.0M	5.6M	8.7M	7.8M	4.5M	5.2M
Total Stockholder Equity	36.9M	36.3M	54.1M	30.5M	13.2M	18.6M
Net Tangible Assets	51.0M	19.5M	22.9M	37.9M	43.6M	45.8M
Retained Earnings	(60.1M)	(90.9M)	(126.2M)	(144.2M)	(157.1M)	(149.2M)
Accounts Payable	3.4M	3.7M	3.0M	2.8M	3.2M	1.8M
Cash	6.1M	17.5M	35.3M	17.0M	2.7M	2.6M
Non Current Assets Total	35.3M	15.1M	17.0M	20.6M	6.4M	6.0M
Cash And Short Term Investments	6.1M	17.5M	35.4M	17.0M	3.5M	3.3M
Net Receivables	1.6M	161.3K	501.0K	374.4K	7.4M	7.7M
Common Stock Total Equity	10.3M	68.1M	98.0M	103.2M	118.7M	124.6M
Common Stock Shares Outstanding	7.1M	12.0M	34.9M	38.7M	39.6M	41.6M
Liabilities And Stockholders Equity	44.0M	42.0M	63.0M	38.4M	17.4M	25.4M
Non Current Liabilities Total	1.0M	1.3M	112.3K	79.1K	131.0K	38.0K
Other Current Assets	329.5K	9.2M	10.0M	471.9K	154.6K	146.9K
Other Stockholder Equity	22.1M	23.8M	27.7M	30.6M	30.1M	31.6M
Total Liab	7.1M	5.7M	8.8M	7.9M	4.5M	5.3M
Long Term Investments	11.8M	1.7M	660.2K	827.6K	6.0K	5.7K
Total Current Assets	8.7M	26.9M	45.9M	17.9M	11.0M	11.1M
Accumulated Other Comprehensive Income	(86.3K)	207.8K	239.6K	652.6K	3.1M	3.3M
Common Stock	75.0M	103.2M	152.3M	143.4M	137.1M	143.9M
Property Plant Equipment	8.3M	12.1M	9.0M	168.3K	193.6K	183.9K
Net Debt	(4.5M)	(17.0M)	(34.7M)	(16.5M)	(2.4M)	(2.5M)
Property Plant And Equipment Net	9.1M	0.0	168.3K	260.9K	119.8K	113.8K
Net Invested Capital	38.4M	36.7M	54.4M	30.8M	13.5M	12.9M
Net Working Capital	1.8M	21.3M	37.2M	10.0M	6.5M	6.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether FSD Pharma Class is a strong investment it is important to analyze FSD Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FSD Pharma's future performance. For an informed investment choice regarding FSD Stock, refer to the following important reports:

How To Invest In FSD

Details

Is FSD Stock a good investment?

Details

What is FSD Pharma's Net Worth?

Details

Largest Drug Manufacturers - Specialty & Generic Companies

View

Largest Information Technology Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in FSD Pharma Class. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

Note that the FSD Pharma Class information on this page should be used as a complementary analysis to other FSD Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for FSD Stock analysis

When running FSD Pharma's price analysis, check to measure FSD Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FSD Pharma is operating at the current time. Most of FSD Pharma's value examination focuses on studying past and present price action to predict the probability of FSD Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FSD Pharma's price. Additionally, you may evaluate how the addition of FSD Pharma to your portfolios can decrease your overall portfolio volatility.

	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	CEOs Directory Screen CEOs from public companies around the world
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Transaction History View history of all your transactions and understand their impact on performance
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities

Is FSD Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FSD Pharma. If investors know FSD will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FSD Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.46)

Quarterly Revenue Growth

(0.07)

Return On Assets

(0.43)

Return On Equity

(0.84)

The market value of FSD Pharma Class is measured differently than its book value, which is the value of FSD that is recorded on the company's balance sheet. Investors also form their own opinion of FSD Pharma's value that differs from its market value or its book value, called intrinsic value, which is FSD Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FSD Pharma's market value can be influenced by many factors that don't directly affect FSD Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between FSD Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if FSD Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FSD Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

FSD Non Current Liabilities Total vs Net Receivables Analysis

Non Current Liabilities Total vs Net Receivables

Non Current Liabilities Total vs Net Receivables Correlation Analysis

Correlation Coefficient

Non Current Liabilities Total

Net Receivables

FSD Pharma fundamental ratios Correlations

FSD Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

FSD Pharma fundamental ratios Accounts

Also Currently Popular

Complementary Tools for FSD Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Common Stock	+ 0.99	Other Stockholder Equity
Total Stockholder Equity	+ 0.98	Total Assets
Other Stockholder Equity	+ 0.98	Common Stock Total Equity
Short Term Debt	+ 0.98	Short Long Term Debt
Total Current Assets	+ 0.97	Cash

Common Stock	- 0.94	Retained Earnings
Other Stockholder Equity	- 0.93	Retained Earnings
Common Stock Shares Outstanding	- 0.91	Retained Earnings
Common Stock Total Equity	- 0.87	Retained Earnings
Accounts Payable	- 0.75	Retained Earnings
Retained Earnings	- 0.72	Net Tangible Assets